Merck enters 2026 with $65.0 billion of 2025 sales and a clear strategic challenge: continue maximizing KEYTRUDA while rapidly diversifying the portfolio before its future loss of exclusivity becomes the dominant financial issue. KEYTRUDA generated $31.64 billion, almost half of company sales, while newer products including WINREVAIR and CAPVAXIVE are beginning to create additional growth engines.
The strategy is science-led but economically disciplined: invest heavily in internal R&D, acquire or partner for external innovation, expand successful products across indications and build a broader portfolio across oncology, cardiometabolic and respiratory disease, vaccines and Animal Health.
For the economics behind the portfolio, read our Merck Business Model 2026.
1. Maximize KEYTRUDA While Preparing for Life Beyond It
KEYTRUDA remains Merck’s most powerful asset. Sales increased 7% to $31.64 billion in 2025 as demand expanded across approved indications. Its broad role in oncology gives Merck relationships with physicians, health systems and research networks that can support additional cancer therapies.
The strategic objective is not simply to grow current sales. Merck can expand KEYTRUDA through earlier-stage treatment settings, combinations and new formulations while using the franchise’s cash generation to fund replacement assets.
KEYTRUDA QLEX adds a subcutaneous formulation, potentially changing administration convenience in eligible settings. Lifecycle innovations can preserve clinical relevance and strengthen the franchise even as Merck prepares for eventual competitive pressure.
Concentration nevertheless creates urgency. Nearly half of company sales came from KEYTRUDA in 2025. Merck therefore needs new franchises to scale before the economics of the oncology leader change materially.
For the associated strengths and risks, see our Merck SWOT Analysis 2026.
2. Build Multiple New Growth Engines
WINREVAIR is an important proof point. Sales increased from $419 million in 2024 to $1.44 billion in 2025, establishing a meaningful cardiopulmonary growth platform. CAPVAXIVE similarly increased from $97 million to $759 million.
Welireg reached $716 million, up 41%, while alliance revenue from Reblozyl increased 41% to $525 million. These products are individually much smaller than KEYTRUDA, but collectively they demonstrate the portfolio diversification Merck needs.
The strategic goal should be several multi-billion-dollar franchises rather than identifying one direct KEYTRUDA replacement. Multiple growth engines diversify clinical, competitive and patent risk while creating a smoother revenue transition.
Launch execution matters as much as regulatory approval. New products need physician awareness, reimbursement, manufacturing capacity and evidence that differentiates them from established treatment options.
For external forces affecting this strategy, read our Merck PESTEL Analysis 2026.
3. Use R&D and External Innovation to Rebuild the Pipeline
Merck invested approximately $15.8 billion in R&D in 2025, equivalent to roughly 24% of sales. This investment supports discovery, clinical trials, regulatory work and lifecycle development across a broad pipeline.
Internal science alone is unlikely to provide every future growth asset. Merck therefore uses acquisitions, licensing and collaborations to access external innovation. This can accelerate entry into new therapeutic areas or add assets that have already passed early scientific milestones.
External innovation carries valuation risk. Competition for promising biotechnology assets can raise acquisition prices, and clinical programs may fail after substantial payments. Merck’s scale provides financial capacity but does not remove scientific uncertainty.
The optimal strategy is a portfolio of development programs across stages and therapeutic areas. A broad pipeline creates multiple shots on goal and reduces dependence on any one clinical readout.
4. Defend and Rebuild the Vaccines Franchise
Vaccines remain strategically important, but 2025 highlighted portfolio volatility. GARDASIL/GARDASIL 9 sales declined 39% to $5.23 billion, largely offsetting growth elsewhere and limiting total company sales growth to 1%.
Merck needs to manage mature vaccine franchises while scaling newer products. CAPVAXIVE reached $759 million in 2025 and VAXNEUVANCE generated $825 million, demonstrating that newer pneumococcal products can contribute meaningfully.
Vaccines have distinct commercial dynamics because public-health recommendations, government purchasing, inventory and vaccination rates influence demand. Geographic conditions can also produce large year-to-year changes.
Portfolio renewal is therefore essential. Merck must continue developing vaccines addressing meaningful disease burdens while maintaining manufacturing reliability and navigating complex national immunization systems.
5. Use Animal Health as a Diversified Growth Platform
Animal Health generated $6.35 billion in 2025, up 8%. Livestock sales increased 13% to $3.90 billion, while companion-animal sales rose to $2.46 billion.
This business provides diversification because its customers, disease markets and competitive dynamics differ from human pharmaceuticals. Livestock demand relates to food production and animal disease management, while companion-animal products benefit from spending on pet health.
Animal Health also creates a separate innovation platform for medicines, vaccines and technology. Its growth can reduce consolidated dependence on human oncology, even though the segment remains much smaller than pharmaceuticals.
The strategic discipline is to invest where Merck has scientific and commercial advantages rather than treating Animal Health merely as a diversification asset. Sustained value requires differentiated products and strong customer relationships.
6. Allocate Capital Toward Durable Post-KEYTRUDA Growth
Merck’s capital-allocation challenge is unusually important because current cash flows are concentrated in a product whose exclusivity will not last indefinitely. Management must convert today’s earnings into future franchises through R&D, acquisitions, partnerships and manufacturing investment.
Acquisitions can accelerate portfolio transformation but should be judged on expected risk-adjusted returns. Paying too much for late-stage assets can transfer future value to sellers, while underinvesting could leave a revenue gap.
Manufacturing capacity also requires capital. Successful biologics, vaccines and specialty medicines need reliable global supply, and new modalities can require specialized processes. Capacity decisions must anticipate demand years ahead.
Shareholder distributions compete with these investments for capital. The strategic priority should remain maintaining financial flexibility to fund high-quality innovation capable of generating durable growth beyond today’s largest products.
Strategic Outlook for 2026
Merck’s 2026 strategy is fundamentally a portfolio transformation. KEYTRUDA continues generating extraordinary scale, but the company’s long-term value depends increasingly on how quickly WINREVAIR, CAPVAXIVE, Welireg and future pipeline assets can broaden the revenue base.
Execution should be evaluated through new-product uptake, pipeline approvals, clinical milestones, vaccine performance, Animal Health growth and the share of revenue generated outside KEYTRUDA. R&D spending alone is not enough; the investment must convert into differentiated medicines with meaningful commercial potential.
The strongest outcome would be a transition from one dominant blockbuster to several durable franchises across therapeutic areas. Merck has the scientific resources and financial scale to pursue that objective, but the timing of pipeline success relative to KEYTRUDA’s lifecycle will determine whether the transition is smooth.
Portfolio transformation also requires careful sequencing. Merck needs to know which new products can contribute meaningful revenue before KEYTRUDA’s economics change. Programs with strong clinical differentiation and large addressable markets deserve disproportionate development and launch resources.
The company can use oncology infrastructure to improve the economics of new cancer assets. Existing relationships with investigators, oncologists and treatment centers can accelerate trials and commercialization, while KEYTRUDA combination studies can create additional routes to market for complementary therapies.
However, Merck should avoid assuming that oncology leadership guarantees success in every cancer program. Treatment standards evolve quickly, and competitors are developing new mechanisms. Each investment must demonstrate clinical value independently.
WINREVAIR shows the strategic value of entering a market with differentiated science. Its rapid growth provides revenue outside oncology and creates a commercial platform that future cardiopulmonary assets may leverage. Building around successful new franchises can improve the return on specialist infrastructure.
Vaccine strategy requires similarly focused portfolio choices. Mature franchises can be highly valuable, but public-health markets can shift quickly. New vaccines need clear clinical value and strong recommendations to create durable adoption.
Animal Health should be managed as a growth business rather than merely a hedge against pharmaceutical volatility. Its $6.35 billion revenue base gives Merck scale to invest in veterinary R&D, manufacturing and commercial capabilities that smaller competitors may find difficult to replicate.
External innovation is likely to remain one of the fastest ways to diversify. Acquiring a scientifically validated asset can shorten development timelines compared with starting from discovery, but later-stage certainty is usually reflected in a higher purchase price.
Merck’s internal R&D organization therefore creates value in two ways: originating medicines and evaluating external opportunities. Strong scientific judgment can help management distinguish assets that genuinely complement the pipeline from transactions driven primarily by the urgency to replace revenue.
Capital allocation must also preserve flexibility. Clinical data can change priorities quickly, so committing too much capital to one acquisition or platform could limit the ability to respond when better opportunities emerge.
Manufacturing investment should follow the emerging portfolio. New biologics, vaccines and specialty therapies may require different facilities and processes. Merck needs enough capacity for successful launches without building excessive infrastructure before demand is proven.
Commercial capabilities should evolve alongside the science. New therapeutic areas may involve different specialists, payers and patient journeys from oncology. Portfolio diversification therefore requires organizational diversification as well as product diversification.
The central strategic test is whether Merck can convert its current scale into a portfolio that is less concentrated by the time KEYTRUDA faces significant competition. Revenue from new launches, late-stage pipeline quality and successful business development are leading indicators of that transition.
Another priority is expanding the contribution from products already showing commercial traction. Welireg, PREVYMIS and alliance products may not individually replace KEYTRUDA, but sustained double-digit growth across several franchises can materially improve diversification over time.
Merck should also use lifecycle evidence to prioritize capital. Products demonstrating strong physician adoption and clinically meaningful differentiation may justify additional indication trials, while weaker programs should be discontinued early enough to redirect resources toward higher-probability opportunities.
Geographic execution matters because nearly $28.5 billion of 2025 sales came from outside the United States. Regulatory approvals, reimbursement and launch sequencing need to convert global clinical programs into international revenue rather than relying disproportionately on the U.S. market.
The vaccine portfolio requires particular geographic discipline. Demand patterns can vary sharply by country and public-health program, so manufacturing and inventory decisions need to respond to local uptake without creating excess supply.
Merck’s partnerships can also extend capital efficiency. Sharing development or commercialization with another company can reduce risk while giving Merck access to complementary science. The tradeoff is sharing economics when products succeed.
Organizational speed is strategically important because large pharmaceutical companies can become bureaucratic. Merck needs rigorous governance without allowing decision processes to delay promising programs in therapeutic markets where competitors are advancing quickly.
Pipeline breadth should not be confused with pipeline quality. The most useful strategic indicators are differentiated late-stage assets, positive pivotal data, regulatory approvals and successful launches—not simply the number of programs listed in development.
By 2026, Merck’s strategic challenge is therefore measurable: increase the absolute revenue generated by non-KEYTRUDA growth products while advancing enough high-quality pipeline assets to create the next wave before current franchises mature.
Commercial execution around new products should also be measured against the scale of the revenue gap Merck ultimately needs to fill. A launch reaching $1 billion is important, but replacing a franchise above $30 billion requires several products reaching substantial scale. This arithmetic explains why diversification must begin years before exclusivity changes.
Merck can improve the odds by expanding successful launches across indications. Once safety, manufacturing and commercial infrastructure are established, additional indications can create incremental growth without rebuilding the entire platform from scratch.
Combination strategies are especially relevant in oncology. KEYTRUDA’s established role can make it a backbone for trials with complementary mechanisms, potentially supporting both the existing franchise and newer assets. Merck must nevertheless prove that combinations create clinically meaningful incremental benefit.
Strategic discipline also requires terminating weak programs. R&D productivity improves not only when projects succeed but when evidence allows management to stop low-probability programs before they consume additional capital and time.
Finally, Merck needs to protect execution quality during portfolio transformation. Simultaneously integrating acquisitions, launching products and running a broad pipeline can strain management attention. Clear therapeutic-area priorities and accountability are essential if financial scale is to translate into scientific productivity.
Merck should also evaluate diversification by revenue quality, not only revenue size. Products with long remaining exclusivity, broad indication potential and strong clinical differentiation can create more durable value than products already approaching competitive pressure.
The company’s 2025 performance makes this transition visible: total sales grew modestly even as several new products expanded rapidly because GARDASIL declined sharply. A broader set of large growth franchises would make consolidated results less sensitive to one product’s annual movement.
Source: Merck & Co., Inc., 2025 Annual Report / Form 10-K.
